Batavia Biosciences and Valneva Sweden AB, the Swedish subsidiary of Valneva SE announced that they have entered into a collaboration agreement to accelerate market-access of a low-cost inactivated polio vaccine (IPV).
Batavia Biosciences and Valneva Sweden AB, the Swedish subsidiary of Valneva SE announced that they have entered into a collaboration agreement to accelerate market-access of a low-cost inactivated polio vaccine (IPV).